Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

BACKGROUND: Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor (TKI); however, post-progression survival (PPS) after EGFR-TKI treatment has not been sufficiently studied. METHODS: We retro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Kogure, Yoshihito, Saka, Hideo, Oki, Masahide, Saito, Toshiki I., Ahmed, Shimaa Nour Moursi, Kitagawa, Chiyoe, Imaizumi, Kazuyoshi
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532435/
https://ncbi.nlm.nih.gov/pubmed/26262682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0135393
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados